PRTK - Earnings call transcript Q1 2021 | Paratek Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings. Welcome to Paratek Pharmaceuticals' First Quarter 2021 Earnings Call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] At this time, I'll turn the conference over to Ben Strain, Vice President Investor Relations. begin. now may you Ben,

Ben Strain

Regulatory and Good on morning President and with Quarter call Earnings will Officer; and earlier Paratek's company's and in Vice Participants posted our website also www.paratekpharma.com. call. welcome Accounting Update Conference Both to that today issued Loh, Evan Corporate questions. was at Chief Chairman; are Development Bigham, Officer for release referred on Brenner, Michael quarter today's First and Commercial Executive Sarah have Call. Chief President also first slides Adam to Controller XXXX be results found Officer; and we this of A will Randy the Woodrow, and available be CEO; Higgins, press be Finance Principal can

certain turn current we making will like and filings for consult to Evan, over Before call Evan? are are and discussed be our SEC the expectations over our beliefs. that risks to statements to based in to out I and risk I you the on point results which to our may additional forward-looking materially. encourage statements uncertainties would subject These factors I differ actual detail.

Evan Loh

with a only of NUZYRA this outcomes of not healthcare believe all Good growth in XXXX year. a achievement of update XXXX also continued for Ben. thank of for the quarter and quarter-over-quarter NUZYRA's rapidly We hands transformative importance growth Paratek. be our the morning positive you, year earnings and the a volatile reflection call. first quarter Thank will joining is evolving clinicians. believe in significant you this setting, corporate We of first continued into in but clinical patient this and

in results were first as with our the of Our quarter, million $XX.X NUZYRA generated first commercial expectations the business. reflecting U.S. of net sales health quarter our XXXX consistent

coupled with expansion. care term new We adaption upon XXXX, NUZYRA spectrum initial signs positive the the based anticipate against setting, of for the physicians feedback growing the commercial care NUZYRA will recent of prescriptions in commercial in that well-tolerated, primary confidence hospital growth skin broad demand of long initial oral, care through Our success and remains includes unabated continue encouraging primary from the based coverage balance the of this MRSA once-daily, inbound antibiotic trajectory for infections. that the a given in

first, commercial to seen differentiate the continues success NUZYRA driven launches care. broad five strong NUZYRA's itself antibiotic NUZYRA's operational to-date favorable of last and most many with enable profile indications; attributes product convenient third, oral in execution multiple consistent tetracycline by once-daily, oral and established NUZYRA a common one and antibiotics across pathogens As IV that of as this next resistant that launched materially in from formulations IV include: heritage; safety in settings utility has successful spectrum including second, efficacy two the the slide, years. other

the to exciting addition focused commercial transformative business, on In we for Paratek. and several catalysts potentially are

of million. to excited BARDA announce initiated $XX NUZYRA procurement we're approximately valued the first First, has at that

We be this this expect will and procurement recognized delivered that quarter.

the we NUZYRA NUZYRA for commercial oral regimen the If loading will pneumonia. in on care believe in sNDA decision FDA for primary the opportunities approved, important important an an Second, setting. further-expand to be the catalyst this dose

part therapies. year. actively our catalysts, for infrastructure. our second we which this to continue of the a the Phase markets, to rare will antibiotic commercial potential leverage potential largest trigger portfolio a abscesses, Third, of the from are NUZYRA second NTM NUZYRA addition there finally, million pulmonary anticipate assets initiation in milestone the of approval evaluate $X to expand Paratek. one we payment to of anticipate ZyLAB which Fourth, China, in And of and Xb these in in we procurement for in approved a disease, approval study Fifth, no half

Before I first would call financial XXXX to to Paratek's hand I now like quarter the highlights. provide Adam,

over in in quarter, quarter prior net and X% an in million, the of increase U.S. $XX.X the and sales quarter XXX% XX% quarter the million of prior an over NUZYRA was increase first XXXX. total XXXX of revenue XXXX. quarter, $XX.X of over First over generated first increase quarter X% the the an first

on-shoring step quarter quarter First million contracts first the up BARDA under and under and of in we anthrax grant revenue at studying service BARDA move service a government advancement U.S. NUZYRA of were in earned XXXX and work year, XXXX. that contract in pneumonia, the earned program. versus as contracts FDA the of through grant the the We $X.X preclinical the million required fourth contract, further continue of quarter the the associated $X.X enrollment anticipate revenue manufacturing for the modest in in with activities the by driven post-marketing

$X.X XXXX, same under the million an the as expense increase partially quarter compensation million for compared focus lower compensation lower organization, U.S. BARDA for expense expense. expenses contract $XX.X million, NUZYRA the SG&A manufacturing were period FDA to First stock-based of R&D as same the up the third year. manufacturing in as first primarily efficiencies for of result were in BARDA continued the The of well quarter were R&D the operational party period to in expenses million is R&D in reimbursed scale the first process contract. costs across clinical requirements. reimbursable result $X.X the incurred in on well year. million decrease for and expense decrease a for driving under quarter the post-marketing stock-based compared $X.X costs, $XX.X as lower for The expenses the primarily and in prior SG&A prior the by on-shoring a of is study Included offset in costs

breakeven. turn cash over flow I anticipate cash XXXX, our XXXX current Adam. runway March call pathway of XX, a $XXX.X million of provides As like now for we to our Adam? upon cash would cash we to through cash in the a cash and had operating existing plan, and equivalents. equivalents with end to Based the

Adam Woodrow

NUZYRA consistent commercialization of in of well progress even with The pandemic. ongoing face Evan. growth to continue its quarter-over-quarter COVID-XX since launch, Thanks, the the

XX, antibiotic to first virtual is Year we are hospital by year to a community and first tremendous for past. ongoing From credibility care. our community encouraging interactions. numbers seen quarter life-saving physicians' initial and our we is community-acquired day. quarter, as gaining results efficiently see New the was care care focus the XXXX lives in both approximately maintain to from Nevertheless, quarter-over-quarter fewer far impacted as compared NUZYRA combined and there positioned utility. data and data second to broad need hospital this hybrid seen the and grew This access, the much This approximately the resistance fourth and unmet continuing revenue The the stays, growth suggests of it's net and profile in the new have as to every spectrum in our in discussed quarter the in Slide every options from face-to-face challenges generic occurring to see concerns, that resets, needed well-tolerated offers in occurs potential setting by that challenged uniquely hospital safety we from the significant the applicable effectively broad saving signs and the is by you well-tolerated We half by sales In shift oral XXXX, coverage prescription impactful treating momentum of the salesforce dynamic utilization have on access infections. care in either model out of for with As $XX.X NUZYRA's so business once-daily in Current year. where intravenous building antibiotic fourth driven and antibiotic year. $XX.X formulations quarter or than new skin that physicians are and a by face-to-face NUZYRA the from of of from first primary care MRSA thus driven through We XXXX playing of our were a challenges expansion, quarter increased quicker steady and sales in training and million includes minimize our more X% COVID-XX will consisted primary interactions calls verified progresses. news once-daily, serious oral but a to to trust as that efforts. our with anticipate limiting million operated first our with institutional pilot related COVID NUZYRA's their grew well the with spectrum demand demand. typical primary serious continue within primary we into last and infections and the bacterial first the this physicians. when awareness expansion gross expansion quarter against NUZYRA of XXXX trial support presented based the addition who can the the recruiting is insurance primary our care be the

the targeted primary approximately have with significant Our XX in focused now representatives is sales near now half following recruitment and first efforts on We that the headcount, focused hospital quarter. team occurred half care. our on

recommending unmet study, $X.X potential addressable also over As which and described effective to the risks plan market skin oral published the XX% last deemed year, regimen, quarter, role fluoroquinolones NUZYRA favored and targeted associated Later segment dose opportunity care with of promotion equally Vancomycin prescriptions billion our only will infections, available. play this anticipated potential addressing the events were highlighted represents community-acquired into agents in after loading antibiotic $X.X in when of be billion for by study Pew for [ph] In recent use The all on the of fluoroquinolones of represents we which market for NUZYRA opportunity. all additional infections. should study with panel reinforces A addressable toxicity focus this community, largest the pneumonia, the primary the reports promotion. and estimated the an inappropriate. expand and always the approval to our estimated adverse can initial XX% fluoroquinolone, pneumonia alternative include needs launch

in NUZYRA panel circumstances. data antibiotics our that, quarters on use And to with for path that are progress in over could reinforced the look result, to the of NUZYRA I'd the turn unmet the reporting We a ahead. success. an XX%. some to important with We As forward to on now continued reduce the each term these and some and national recommended suggest we're well-positioned This by commercial call clinical right believe like inappropriate target a clinical needs for alternative Randy. long provide

Randy Brenner

Adam. Thanks, Thanks.

As from to quarter. this are that first that we a Evan procurement initiated we excited $XX ago, approximately be NUZYRA valued of the BARDA delivered announce million you at few will minutes heard has expect

advance to contract. manufacturing preclinical, clinical continue BARDA and also the We the under work

for activities by with startup BARDA to in expected Phase pneumonia post-marketing pipeline pulmonary our are addition of In activities, the next NTM progressing recent we initiation FDA. study disease the required and study abscesses rare Xb our initiation study with the the month

NUZYRA. acquired to bacterial actively our are decision FDA continue this from pursue lifecycle for oral initiatives regimen loading community for Later anticipating on dose month, a We our for sNDA the pneumonia. we

to continue our also abscesses, disease NTM. for We tuberculous clinical mycobacteria development non or rare disease, by mycobacteria advance pulmonary our caused program

the with As an to pulmonary addressable upon abscesses pulmonary well-tolerated is oral market unmet estimated has Mycobacterium from internal our by the caused to in treat for Based clinical efficacious obsesses billion abscesses. disease therapies. need Mycobacterium represents $X no FDA-approved Inbound continued antibiotic a market alone. an reminder, community analytics, KOL highlight NTM infections the feedback U.S. and an once-daily orphan

startup in initiation planned Phase of our disease are for the the June. the for in this with in study study Xb We advanced activities

meeting We in the be efficacy near will the details and an and to which microbiology exciting symptom includes about opportunity significant to provide at safety assessments address needs. for unmet medical term. with NUZYRA announced is potential NTM upcoming important an endpoints, more lifecycle

Strategic public a to pathogens, in the antimicrobial bio-terrorism continues National anthrax Our unique our partnership potential of to is for resistance also NUZYRA BARDA and recognition against and of in fight develop commitment This private Stockpile. the NUZYRA treatment jointly partnership progress procurement the shared advancing as against including NUZYRA to well.

the this progress U.S. our animal antibiotic be NUZYRA only over U.S., production. the potentially animal to generated our in enable chain advancing will the procurement, efforts our to with to addition the against additional and program, in the that to important secure manufacturing the anthrax regards of the news be roll will best first continue API as to we isolates made onshore NUZYRA make us XXX In have including within pathogen. first Bacillus With supply we, that program, anthracis of exclusively continues initiating data for vitro To in of NUZYRA knowledge, to life-threatening to potency roll confirm BARDA along as anthrax NUZYRA well

this to strains, and doxycycline. resistant its potency a in with also Against of ciprofloxacin remained Importantly, strain vitro included a separate strain active resistant these to Omadacycline testing both maintained.

anthracis. other against multi-drug this strain to that and pandemic retained multi-drug States received many also antibiotic suggesting work with as known resistance Army panels data, data Institute resistant be testing antibiotic resistant of potential Against support Omadacycline In we data NUZYRA addition activity vitro resistant various the Research for anthracis, This of for the strains conducted strain USAMARIID, its of only all against originally could the potency, a resistance we strains in to including option classes. NUZYRA Omadacycline Disease, preparedness of Infectious Bacillus viable resistant in utility multi-drug and biothreats. Bacillus United

at biologic types at threats. NUZYRA and bacterial or shown for presented in resulting the has plague. the included plague, with or Association the the the for pathogens of Health secondary a it's had pathogen nuclear the this conference, on shown radiologic, [ph] for National several highlighted threat. chemical, this looking as exposure our and/or Preparedness closely from list post poster Officials the of addition, pathogens. [ph] recommended in CDC alternatives in a green XXXX County Summit We're regarding poster, from recent vitro In highlighted was approved Asper City and infections prophylaxis the another In pathogen pre as potential infection boxes, of poster. poster challenges of already USPI either in Omadacycline address pandemic further treatments the NUZYRA that this to key boxes, at Also blue in data or these confirming the indication

the open CDC future further to in Paratek. specialists potential update on process threats, story we primary The number of NDA base. utilization continues medical program. of good education of year, and With Omadacycline As believe community the to and we'd point, This triggering China, to the based regulatory regards with reach the ZyLAB launch. further a believe in NUZYRA recent advancement includes patient small highlight that XXXX U.S. has continue of the team questions. news augment to to for important from Omadacycline posters and clinically believe will like two targeted for placement this the list review education several scientific China the summer. planned into opportunities data pneumonic continue new payment the populations. to plague the progress, further broaden guidelines the The for make a the throughout $X of approval potential a milestone line a additional We expand to government care the anticipated to approval to this new million launch community the with these their utility opportunities activities expected result, later expansion to we this At open growing generation to We include further healthcare into the will IRR and continued of support scientific the and with the this affairs procurements. our has potential

Operator

question Thank Wainwright. of proceed line live. you. [Operator your is Instructions] Our from live H.C. line Please, Ed Mr. for questions. Arce, questions. is with first Arce Mr. your your Arce, line is the with

Our BTIG. your next line with from Bert Please, of coming proceed the question. with question Hazlett is

Bert Hazlett

terrific, and terrific It's on an been quite results. Congratulations been levels. effort number of it's a

thoughts with congratulations of some as And all us on military Just NTM? that least, broadly? Xb other you as to secondly, mentioned, further you've again. three love confidence the once for in primarily thinking Then additional you government, the give with last are and but further brief procurement, or ones. the more Omadacycline, some enrollment Could timetable just regard your or expansion there. Thanks we progress is contemplate then product not portfolio study

Evan Loh

first Thank the very questions. the around much have Bert. you for I'll Hi, address timeline. Randy question

Randy Brenner

Hey, Evan. Thanks, Yes. Bert.

said announcing we and that more soon. this on a that So, patients study. be in NTM enrollment update a two-year providing process numbers We've that the for upcoming of study will an detailed the we'll much size meeting expect we on about the of be based population, in our study

Evan Loh

the... and Okay, then

Bert Hazlett

potential of Omadacycline? then Terrific. for or then government there with either And the without procurement your and expansion potential and enthusiasm additional

Evan Loh

Yes.

do are within being to that the We initiated We here. public the is extremely procurement our think validating private partnership. excited commitment about tremendously that

added addition I comment Adam In could joint possibility efforts last of exploring. as was the the formulary, procurements think that, Maybe NUZYRA the has to some year on I been which the Defense. throughout up Department to a of reminder, deployment for his team future that have opens broader

Adam Woodrow

to to the Yes, the add early NUZYRA efforts. such of and departments to continue therapeutic the hi, Military. stockpiling option we successful Stockpile Strategic within be Defense National explore assured to with for try opportunities, continue hard. you, rest these choice to government we'll number Look, future stimulus could buyer departments how But Evan. about threats as other Thank of a the engage we'll and package. Department with ideal be a an with we'll Bert. and recent new too It's especially predict

Evan Loh

And to question hospital think expansion, community sector monitor product setting, regards and gives think a we the closely. to consider Omadacycline potential imagine, both third expand commercial And presence else. us, something the Burt, your opportunities our Look, in I very you or having as with now I'll to Bert, to our can pipeline. regards greater take flexibility with I

commitment lead opportunities has been always our asset, first around to NUZYRA. build around Our

infrastructure to ensure core opportunities franchise and excited Randy our expanding NUZYRA competencies our our heard from about, we're product You lifecycle established successful. to and which be that today about given the expertise

we'll for look monitor these our approach position assets, strength, disciplined can assets. continue bring runway. we But potentially we though, cash our believe our carefully of always, as in to we remain Given and additional in

Bert Hazlett

Congratulations again. you. Thank

Evan Loh

Thank you, Bert.

Operator

of question. your with line from G. Kedra Our proceed Kevin Please, with next Research. question is the

Kevin Kedra

taking Hi. questions. procurement, you remind later initial Thanks from any expect you this congratulations needed BARDA. that for procurement second us moving the first, on for the that Can of getting Maybe deliverables year?

Evan Loh

Randy, you want that take to one?

Randy Brenner

sure. Yes,

Kevin. continue So, commitment We're exactly excited thanks, BARDA's certainly program. advancing procurement; we to achieved to exemplify that first the the

for procurement continue in this half to this second plan We the second of year.

the As milestone no of progress tied we've of assigned There's continued to specifically ongoing the procurements specific to them. future each are to program. state,

more the continue about we'll timing with exact to procurement half have in discussions So, the future second year. provide the BARDA and that to the specifics of

Kevin Kedra

next of Omadacycline everything to kind over switching How Or cap the season had expect still guys bit start cap Do closer a lot you of then year normal? you heading into And COVID. as disruption winter? season? to are thinking something with to of abnormal that's next in this going you do with cap, we anticipate this we Great. feel COVID an about a

Evan Loh

the across success instilled drove at of rate really a successful. the pneumonia U.S., seeing with rates that throughout improving rigorous I resources we well COVID in provide As masking, think that programs I health as been was that lower populations. program commitment very included to to washing, regards the health public seen vaccination than the And the that has that we're said, think for look excited during our a being about pandemic, been all to the have as that social hand company decades. measures was interesting what as distancing, the community-acquired we're vaccination That many were

see dynamic think folks where given a the another I basis interaction said, fact able because fall most I I we'll CDC trends a strategy being keep such, pneumonia, for be the hospitals them to play think fall. being are will keep have hospital I that the with trying season. start more see community of potential play as loading out be NUZYRA And there think most in very skin about growth With pre-pandemic home MRSA the patients the of and think the the with to bit, we our pneumonia be in more on expansion more opportunity there into a an there patients I that normal to aspect with interact do think think concentrated [ph] if expansion That and that been the and a people places oral-only of well will expansion, come continued to into will guidances, to mass-less is I our see fall. growth to those we recent started think are the that come very considerations, And dose home for COVID, community I there. for quite stay launch doctors with the cautious ill this in who and referring infections, regards a as of I will especially effort think franchise

Kevin Kedra

you in Would with contract governments that. you last -- U.S. governments the well? Can opportunities to in one. approved other the as talk in Maybe have would these countries Do would Great. to you opportunities in have least the you be approval discussions? mentioned see Or discussions able before those stockpiling before markets? need Appreciate beyond initial U.S. NUZYRA NUZYRA government at you with of about those you BARDA. have or have opportunities international with you

Evan Loh

Yes, address thanks have for that that. I'll one. Randy

Randy Brenner

Sure.

attention yes, pay what's around are regards antibiotic includes for with on to the to continuing going potential which incentives stockpiling. So we some world to

bio You've those our require A provide countries antibiotic regulatory continue pandemic on well. countries. for of ongoing particularly to That and opportunities for of ways are continue X probably those [ph] many dose to stockpiling database, thinking look approval buyer as data now look expand activities doing we as U.S. resistance some of threats about that in to opportunity to will threats, precursor being share well. and for and read we to countries to opportunities European for the those look preparedness said, to some as

Evan Loh

a can add commitments around from bread the look the ignore a will to at as pneumonia Randy for we the for, you as hard mentioned you franchised I category, of skin line the preparedness see pandemic think and second listing essential what moving is for more opportunities appropriate. perspective recent we of plague, will NUZYRA et his think that having not are fact, that said, something as I what butter can that think just product that specifically NUZYRA the option presentation, build U.S. it think to CDC of only in preparedness the profile very In that bioterrorism the we a well as And of to do of on Randy this point in Kevin, medicines if poster internally infections, cetera. explore and lead of terms government portfolio and doing commitments DOD U.S. on be BARDA, in I that I are other by outside others to

Kevin Kedra

Thank you.

Evan Loh

Thank you, Kevin.

Operator

Thank Suji you. from line with The Jefferies. is Please, next question the question. of your proceed Jeong with

Suji Jeong

Thanks Hi. question. taking for my

So, up trial. Phase sorry, the do trial the about first missed I NTM to design? I one follow but share is Xb And I'm earlier, expect it questions. you have when

Evan Loh

yes, So NTM the in detail, review meeting in to study really future design. near planning the we're a more

once coming and date more Ben share think will shortly to we that's meeting. were information So, I the able provide of that

Suji Jeong

Thank you.

Evan Loh

no approach innovative broadly us all share be that therapies of oral fact the to really for meeting that looking relatively disease, shortly. more able we I in there That for that and are being there's that we'll forward announce are to being terms an opportunity said, here think in to given approved upcoming that Suji, this

Suji Jeong

on expect expansion to support the My impact the for to full salesforce add And Okay, setting? to questions the to do do see are NUZYRA their you in you expansion community the How CABP expect of care the you. of [ph]. sales? into next additional second the many community Thank you. question is of the indication primary on salesforce when thank setting

Evan Loh

to one? want Adam, do take you that

Adam Woodrow

order, that. Yes, all, I'll of actually. Evan. in reverse those first take Thanks, I'll Well, take

as latter force be move obviously quarter, up just We really what the expect the are pleased with full signs this into to extremely speed first the of quarter early field getting impact the of This will in in [ph] But we're encouraging recruited the year. we've see to and second impact and was the real is we half the seen. second in realized half. expansion

in launch a answer whether new would simply no. steady beyond sort is be, support is that the the expand significantly additional state and don't with simply which community-acquired cap plan need the that As need having many community. representatives the based where representatives about prescribed hospital regards the of of to the We for on overlap we the skin to about to [ph], be And pneumonia. XX-XX individuals prescribe to that those that XX also we reason

those And double-hit that individuals targeting. so you on you're get a

Both your you might little the diseases summer winter. the can bit. pneumonia skin as a more bit You seasonal, these There's are of a in shift imagine. and in focus more infections

So, other at in And order indication you one might positions the some than reverse of detailing. certain you may on time. for rather point over-index your

at we we've we're with putting on in As if we'll past, until benefit. stated we'll the that in the that feel that ground future. we're representatives the sometime and lots the we very look can of as careful putting And realize lots sure benefit from more in,

Evan Loh

the in physicians setting being the other product we consider, Suji, important individual of to I how the a hospital important the primary to expanded one have component think, foundation to patients and infectious think was we've prescriber. in that which sickest the is the of believe that credibility always it that solid of I timing think disease the an I with community, is the establish,

I able see I a pandemic robust think the insurance resets The other right of still and were I feature COVID the reasons of first think believe the quarter-over-quarter to of of do here, of for the setting quarter And operational despite predicate successful our the efforts think we were we those date. the to access includes that the our robustness, some headwinds, in and market support for conditions efforts community for growth a underlying part this expansion year.

Suji Jeong

Thank you. Okay, great.

Evan Loh

Suji. you, Thank

Operator

the from your questions. H.C. is Our question next with Wainwright. Ed with Please, line of proceed Arce

Ed Arce

phone Thanks guys. congrats quarter. on Apologies earlier. Hi, questions procurement for issue this the with part of taking the my first and the for

is of couple questions regarding First NUZYRA.

with us the Firstly, for hearing cap bit expansion tie care year there's for primary there's you as hopefully will broadly, now certainly you're the given to was later of discuss community, of label started more I year? that expectations your oral roughly just I that in -- into for feedback the the early getting, think And the the physicians latter COVID, the as an this half well -- the how wondering, this is But back Thanks. then more of you're reimbursement. It's you February. growth engagement been what how wondering you year? from you had a that for a just NUZYRA of month. remainder the you're the expecting will what months Maybe hearing if can in know as think think and I you're of unfold us of expand you three look physicians, through and give this in cycle detail sort bit

Evan Loh

Thanks, Adam, those that can expansion how bit and in Maybe that with hearing help the regards oral-only inbound success we're projected Ed, questions. the about your loading for to a will little dose about the potential talk you for the fall.

Adam Woodrow

Yes.

how bulk research. oral as asked for pneumonia, of some boards what the on conducted on which a skin seeing. MRSA drug and feedback middle going skin see to and we're simple. about to we've the that With we're since we've sure, of the really February. And market has is a signs we that season, seeing what absolutely of Look, through based that year. Physicians done number are uptake the are The we'll coverage. continue side with in we're different, we're advisory you All regards this uptake. Ed, slightly go getting also is desperate good the really in we're encouraged very it's So, pleased good with we're once-a-day

affects monotherapeutic with slightly be regard and NUZYRA and different. they're What good used in the it's of that's relevant Unfortunately, is drug safely forward with to that QTc [indiscernible]. that along a quite older you Here, that on a see some drugs of drug that to the a are patient coverage can issue bit the cause elderly looking something with population the the doesn't the pathogens with market. that

story of community a and in about community all it's as -- because much an story, skin, pneumonia the So, safety acquired as the MRSA it's efficacy drug. acquired in in once-a-day efficacy

know of therapies good that and pneumonia based we'll a perspective are only sure The and some target needs they've out advantage quinolones from physicians on going significant the form for we're efficacious are in along there the limitations once-daily their and appropriate oral to take with get those we that. we'll we're that got really today uptake. dosing, So, safety

Evan Loh

that We of as to the care the future seeing, second primary exciting and provided be for think growth Ed, point year, in setting, in in all throughout balance and has to prescriptions think this our an time. NUZYRA. I to in the think strong in growth us start of for expanding in to this journey for for you growth I of. forecasting and the of demand continued adaption really of of NUZYRA of I midst the your blockbuster real will of belief at as us confidence that of question in challenges half we're coupled be might be continue every But believe that's in company to the to the I pandemic know, we commercial year, on potential the terms continued continued us regards the fuel think the COVID how with the think part continues be

contribution that growth includes think, think purchases event care, as we've approval that mentioned components in loading growth our organic BARDA overall the commitments, that half of said, potential further sNDA well I continued a Adam addressable many I other second procurement, dose. to and has for FDA get as we as market for that institutional oral a our expansion what in in potential DOD our for are there second estimated the opportunities primary

all and about of So we remain that. [indiscernible] excited

Adam Woodrow

And the we behest seeing. at the year. to we're And Evan, of lifting the through go that hospital we restrictions the anticipate of and face-to-face [ph], a we also more the already impactful see move I interactions as would add that continuing some

Evan Loh

for the Adam. you Thank Thank for you, Ed, questions. that,

Operator

Thank you. to Evan At Loh this end question-and-answer reached time, session. the closing the we've call remarks. over I'll for the turn of

Evan Loh

to call. are there will no closing, questions, more we all I'd As your today's you today. In and attention conclude like for thank time

making The us. journey interest commercial underway. Your a important of well and continued NUZYRA NUZYRA are success to in Paratek is

expand. As continues the data microbiological NUZYRA and wealth studies clinical of to on outcomes

interest. who have progress. appreciate physicians are We studies is of The ahead each passionately much like life-saving bedside participated effective novel be and opportunities Paratek. continued you antibiotic thank We lives, your our antibiotics available NUZYRA every support to NUZYRA provide for particularly are would and forward confident to the and who We Goodbye resistance now. all potential selfless keeping those for and patients of of the increasingly who look of here day. employees a our addition to at and us tirelessly to very armamentarium in the We worked provide our be to clinical concern. to at healthcare have and a in need patients patients where to us apprised to to and the in of save to an dedicated continued able professionals much-needed motivates

Operator

This conference. concludes today's

You this participation. for may disconnect your at you Thank time. lines your

Paratek Pharmaceuticals (PRTK) 17 May 212021 Q1 Earnings call transcript